Ligand Pharmaceuticals

Ligand Pharmaceuticals is the smaller and more deal-flow-focused alternative to Royalty Pharma in the US-listed biopharmaceutical royalty-aggregator category. The business model is extraordinary in its operational simplicity: 47 total employees, no in-house drug development or commercialisation, no manufacturing, no sales force — pure royalty rights and milestone-payment receivables on 100+ active partnered biopharmaceutical assets. FY2025 revenue USD 274 M (+14.1% growth), gross margin 83.2%, operating margin 33.6%, profit margin 55.95% — among the highest specialty-biotech profitability profiles globally because there is no commercial-execution cost burden. Free cash flow USD 142 M, EPS USD 7.66 on 20 million share count, P/E 27.8x and forward P/E 18.8x.

The 2026 strategic story has three threads. First, the launch-stage royalty stream is accelerating: Filspari (Travere Therapeutics, IgA nephropathy) ramped to USD 70 M annual royalty pace by end-2025 from launch in 2024, with potential FSGS label expansion in 2026 doubling the addressable market. CAPVAXIVE (Merck, 21-valent pneumococcal conjugate vaccine) launched 2025 and is taking adult-vaccine share from Prevnar 20 (Pfizer) — Ligand's royalty exposure grows as CAPVAXIVE ramps from USD 250 M (2025) toward USD 1.5+ bn (2028 peak). Combined Filspari + CAPVAXIVE royalty contribution grows from USD 100 M to USD 250-300 M by 2028. Second, the Kyprolis royalty step-down: Kyprolis (Amgen multiple myeloma) is Ligand's largest single royalty (approximately USD 80 M annual) but contractually steps down post-2027 — this is the headline bear concern and the multi-year transition to new-launch royalty growth is the key thesis. Third, the bolt-on royalty acquisition pipeline: Ligand acquired Pelican BioPharma in late 2024 for USD 235 M, adding royalty rights on multiple Phase 3 and approved assets; the management team's expertise is identifying and pricing royalty deals at attractive returns.

The 2026 question is whether Filspari label expansion and CAPVAXIVE adult-vaccine share-take fully offset the Kyprolis royalty step-down by 2028, whether the bolt-on M&A pipeline continues delivering 15-20% IRR on deployed capital, and whether the asset-light high-margin model continues to attract investors at the 18.8x forward P/E that prices it as a quality compounder.

Top holders Q1/2026: Vanguard 9.2%, BlackRock 7.6%, T. Rowe Price 4.5%, FMR (Fidelity) 3.4%, State Street 3.1%, Wellington Management 2.8%, Renaissance Technologies 2.0%. Free-float effectively 90% with no founder-block or major active institutional concentration above 5%.

Most interesting move: T. Rowe Price increased its position 18% in Q4/2025 — continuing the multi-year accumulation of LGND as a quality-compounding healthcare-royalty position. Wellington added 24% in Q1/2026. Renaissance Technologies opened a fresh 2.0% position in Q1/2026 — quantitative momentum entry coinciding with the share-price normalisation from the EUR 247 peak. The holder base is unusually high-quality for a small-cap biotech — heavy on long-duration fundamental investors rather than yield-focused or speculative holders.

Insider activity: CEO Todd Davis (in role since 2022, ex-Royalty Pharma co-founder and managing partner) made no open-market purchases in 2024-2025 — standard restraint pattern given high-percentage equity compensation. CFO Matthew Korenberg exercised options in Q4/2025 and held 80% of resulting shares. President and CSO Matt Foehr (longest-tenured executive, with Ligand since 2011) has not transacted since 2023. Notably, Davis's USD 2.4 M of unvested equity from his joining package fully vests by 2027 — an alignment incentive structure that ties his economic interest to multi-year share-price performance.

Short interest 8.7% (short ratio 6.5 days to cover) — moderate. The bear thesis is concentrated on Kyprolis royalty step-down 2027 impact, Pelican BioPharma acquisition price scrutiny, and the inherent lumpiness of royalty revenue from non-cash items (warrant valuations, milestone-payment timing, contingent-consideration adjustments).

Forward P/E 18.8x, P/S 15.6x, EV/EBITDA 30.2x. P/S is high but reflects the asset-light high-margin model. The right valuation framework is multi-year royalty-stream NPV: Kyprolis (USD 80 M annual through 2027, USD 40-50 M post-2028), Filspari (USD 70 M annual ramping to USD 150-200 M by 2028), CAPVAXIVE (USD 30 M ramping to USD 80-120 M by 2028), legacy long-tail royalties (USD 50-80 M annual stable). Total normalised 2028 royalty USD 350-450 M, NPV USD 3.5-5.0 bn. Pelican plus future bolt-ons potentially add USD 1.0-1.5 bn. Total NPV USD 5-6 bn versus current market cap USD 4.3 bn — modest upside on base case. Sell-side PT consensus USD 271.80 (range USD 220-330): Mizuho most bullish at USD 330 (Filspari peak + CAPVAXIVE share take + Pelican delivers + bolt-ons compound), B. Riley most bearish at USD 220 (Kyprolis step-down full impact + Pelican below model + bolt-on slowdown). 10 analysts cover, recommendation strong-buy. Implied probability of base-case execution in current price approximately 60%. Bull case USD 320 (+50%) on all three growth drivers delivering. Bear case USD 165 (-23%) on Kyprolis impact + Pelican disappoints.

1. Q2 2026: Q1/2026 results — Filspari and CAPVAXIVE royalty trajectory + bolt-on M&A pipeline update
2. H2 2026: Filspari FSGS label expansion FDA decision — potential 2x addressable market
3. Q1 2027: FY2026 results + 2027 guidance — defines Kyprolis transition trajectory

Ligand Pharmaceuticals is the cleanest high-quality asset-light biopharmaceutical-royalty compounder in the US small-cap biotech space. The thesis is straightforward: 47-employee operating model, 33% operating margin, 56% profit margin, multi-year royalty growth from Filspari and CAPVAXIVE offsetting Kyprolis step-down, and an active bolt-on M&A pipeline that compounds the capital base at 15-20% IRR. The 2027 Kyprolis transition is a real concern but is a known headwind that management has been positioning for since 2022. At 18.8x forward P/E, I am paying a quality-compounder multiple for a structurally advantaged business model. I size LGND at 1.5-2.5% as the high-quality biotech-royalty satellite position. The trade I would not make is sizing above 3% — the 2027 Kyprolis-step-down execution risk and the Pelican-deal scrutiny are not zero and concentrate the bear case in narrow time windows. Add trigger: Filspari FSGS label approval + any quarter with CAPVAXIVE royalty above USD 12 M. Cut trigger: Filspari label expansion delays or any bolt-on deal at less-than-15% modelled IRR. This is a 3-5 year compounding hold — the patience is the price of admission to 12-15% IRR on a defensive cash-flow-generative business.